A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome (NCT06847867)
A Phase 2, Randomized, Open-label, Study of Momelotinib in Participants With Anemia Due to Low-risk Myelodysplastic Syndrome
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (39 Sites)
Showing the first 25 of 39 sites.
- GSK Investigational Site — Goodyear, Arizona
- GSK Investigational Site — Duarte, California
- GSK Investigational Site — Irvine, California
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Canton, Ohio
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Calgary, Alberta
- GSK Investigational Site — Toronto, Ontario
- GSK Investigational Site — Le Mans,
- GSK Investigational Site — Nice,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Poitiers,
- GSK Investigational Site — Toulouse,
- GSK Investigational Site — Münster, North Rhine-Westphalia
- GSK Investigational Site — Dresden,
- GSK Investigational Site — Leipzig,
- GSK Investigational Site — Udine, Friuli Venezia Giulia
- GSK Investigational Site — Catania,
- GSK Investigational Site — Florence,
- GSK Investigational Site — Milan,
- GSK Investigational Site — Orbassano to,
- GSK Investigational Site — Rozzano MI,
- GSK Investigational Site — Chorzów, Silesian Voivodeship
- GSK Investigational Site — Warsaw,
- GSK Investigational Site — Seongnam-si Gyeonggi-do,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Myelodysplastic Syndromes
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
- Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
- A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
- Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
- Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
- CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida
Explore by condition: All Myelodysplastic Syndromes clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.